The Global Topical Wound Agents Market size is expected to reach $2.5 billion by 2030, rising at a market growth of 8.4% CAGR during the forecast period.
The unique nature of surgical and traumatic wounds drives the demand for diverse wound care agents. Thus, the Surgical & Traumatic segment acquired $170.6 million in 2022. The topical wound agents market responds with specialized products that address specific wound types, promote healing, prevent infections, and improve overall patient outcomes. Technological advancements and adherence to clinical guidelines contribute to the ongoing innovation and development of wound care solutions for surgical and traumatic wounds. Some of the factors impacting the market are rising prevalence of diabetes and road accidents, growing incidence of post-surgical wounds, and high cost of chronic wound treatment.
Diabetes can lead to various problems, such as impaired healing of wounds, lowered immune system activity, and poor circulation. The need for wound care supplies and services grows along with the number of people with diabetes. This demand is driving growth in the market. Diabetes is a significant factor in developing chronic wounds, such as diabetic foot ulcers. With the global increase in the prevalence of diabetes, there is a corresponding rise in the number of individuals at risk of diabetic wounds. According to a WHO report on April 5, 2023, the number of individuals with diabetes expanded from 108 million in 1980 to 422 million in 2014. In low- and middle-income countries, prevalence has risen more rapidly than in high-income countries. Diabetes and diabetic kidney disease caused an estimated 2 million fatalities in 2019. Additionally, surgical procedures frequently result in surgical site infections and wounds, characterized by their increased depth and size compared to other incisions. The discharge of fluids from these surgical wounds necessitates appropriate wound care management; thereby, there is a high requirement for topical wound agents to deal with post-surgical wounds. Post-surgical wounds, including incisions and surgical site infections, necessitate specialized wound care products to promote healing and prevent complications. The market has witnessed a surge in demand for topical wound agents tailored for postoperative care, such as antimicrobial dressings and wounds. Surgical site infections (SSIs) are a significant concern after surgeries, leading to prolonged hospital stays, increased healthcare costs, and patient discomfort. There is a heightened emphasis on wound care products with effective antimicrobial properties to reduce the risk of SSIs and promote faster healing.
Further, the COVID-19 pandemic significantly impacted various sectors within the healthcare industry, including the topical wound agents market. During the initial phases of the pandemic, healthcare resources and attention were diverted towards managing COVID-19 cases, leading to a temporary shift in priorities. Non-urgent medical procedures, including specific wound care treatments, were postponed or delayed, affecting the demand for topical wound agents. Topical wound agents offering antimicrobial or antiseptic properties gained attention due to their role in reducing the risk of wound infections. Therefore, the COVID-19 pandemic moderately impacted the topical wound agents market.
However, chronic wounds take longer to heal, and the prolonged healing process requires continuous monitoring, dressing changes, and ongoing care, leading to increased healthcare resource utilization and associated costs. Chronic wounds often necessitate specialized wound care products such as advanced dressings, bioactive agents, growth factors, and antimicrobial agents. These products are generally more expensive than standard wound care supplies, contributing to higher treatment costs. These services can be expensive and contribute to the overall cost of managing chronic wounds. Hence, the high cost of chronic wound treatment is impeding the market growth of topical wound agents.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Smith & Nephew PLC, Teva Pharmaceutical Industries Ltd., Molnlycke Health Care AB, Viatris, Inc. (Mylan N.V.), AstraZeneca PLC, Coloplast Group, Novartis AG, Pfizer Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), and ConvaTec Group PLC.
The unique nature of surgical and traumatic wounds drives the demand for diverse wound care agents. Thus, the Surgical & Traumatic segment acquired $170.6 million in 2022. The topical wound agents market responds with specialized products that address specific wound types, promote healing, prevent infections, and improve overall patient outcomes. Technological advancements and adherence to clinical guidelines contribute to the ongoing innovation and development of wound care solutions for surgical and traumatic wounds. Some of the factors impacting the market are rising prevalence of diabetes and road accidents, growing incidence of post-surgical wounds, and high cost of chronic wound treatment.
Diabetes can lead to various problems, such as impaired healing of wounds, lowered immune system activity, and poor circulation. The need for wound care supplies and services grows along with the number of people with diabetes. This demand is driving growth in the market. Diabetes is a significant factor in developing chronic wounds, such as diabetic foot ulcers. With the global increase in the prevalence of diabetes, there is a corresponding rise in the number of individuals at risk of diabetic wounds. According to a WHO report on April 5, 2023, the number of individuals with diabetes expanded from 108 million in 1980 to 422 million in 2014. In low- and middle-income countries, prevalence has risen more rapidly than in high-income countries. Diabetes and diabetic kidney disease caused an estimated 2 million fatalities in 2019. Additionally, surgical procedures frequently result in surgical site infections and wounds, characterized by their increased depth and size compared to other incisions. The discharge of fluids from these surgical wounds necessitates appropriate wound care management; thereby, there is a high requirement for topical wound agents to deal with post-surgical wounds. Post-surgical wounds, including incisions and surgical site infections, necessitate specialized wound care products to promote healing and prevent complications. The market has witnessed a surge in demand for topical wound agents tailored for postoperative care, such as antimicrobial dressings and wounds. Surgical site infections (SSIs) are a significant concern after surgeries, leading to prolonged hospital stays, increased healthcare costs, and patient discomfort. There is a heightened emphasis on wound care products with effective antimicrobial properties to reduce the risk of SSIs and promote faster healing.
Further, the COVID-19 pandemic significantly impacted various sectors within the healthcare industry, including the topical wound agents market. During the initial phases of the pandemic, healthcare resources and attention were diverted towards managing COVID-19 cases, leading to a temporary shift in priorities. Non-urgent medical procedures, including specific wound care treatments, were postponed or delayed, affecting the demand for topical wound agents. Topical wound agents offering antimicrobial or antiseptic properties gained attention due to their role in reducing the risk of wound infections. Therefore, the COVID-19 pandemic moderately impacted the topical wound agents market.
However, chronic wounds take longer to heal, and the prolonged healing process requires continuous monitoring, dressing changes, and ongoing care, leading to increased healthcare resource utilization and associated costs. Chronic wounds often necessitate specialized wound care products such as advanced dressings, bioactive agents, growth factors, and antimicrobial agents. These products are generally more expensive than standard wound care supplies, contributing to higher treatment costs. These services can be expensive and contribute to the overall cost of managing chronic wounds. Hence, the high cost of chronic wound treatment is impeding the market growth of topical wound agents.
End-use Outlook
Based on end-use, the market is categorized into hospitals, clinics, and others. In 2022, the hospitals segment registered the highest revenue share in the market. Hospitals are in high demand for wound treatment due to several factors that require specialized care and expertise. The complexity and diversity of wounds encountered in hospital settings and the need for specialized care, infection control, and emphasis on achieving positive patient outcomes contribute to the high demand for wound treatment and specialized wound care agents within hospitals.Application Outlook
On the basis of application, the market is segmented into chronic wounds and acute wounds. In 2022, the acute wounds segment attained a noteworthy revenue share in the market. Acute wounds often include surgical incisions resulting from various surgical procedures. The demand for wound care agents tailored for acute wounds continues to grow, driven by the need for practical, evidence-based products that facilitate optimal healing, infection prevention, and patient comfort while managing various types of sudden injuries and post-surgical wounds.Chronic Wounds Outlook
The chronic wounds segment is further subdivided into diabetic foot ulcers, pressure ulcers, venous leg ulcers, and others. The pressure ulcers segment held a noteworthy revenue share in the market in 2022. Pressure ulcers are a significant healthcare concern, especially among elderly individuals, immobile patients, or those with limited mobility. The prevalence of pressure ulcers in healthcare settings drives the demand for effective wound management solutions. These are crucial in facilitating wound healing and managing pressure ulcers by promoting tissue repair, reducing infection risk, managing fluids, and alleviating patient discomfort.Acute Wounds Outlook
The acute wounds segment is further subdivided into surgical & traumatic and burns. In 2022, the burns segment recorded a remarkable revenue share in the market. Burn injuries, particularly severe burns, create a substantial demand for specialized topical wound care products that cater to the unique needs of burn patients. The market responds by offering diverse wound care agents to address the complexities associated with burn injuries, focusing on infection prevention, pain management, wound healing promotion, and overall patient comfort and recovery.Product Outlook
Based on product, the market is divided into creams, gels, sprays, and others. In 2022, the creams segment garnered the highest revenue share in the market. Patients and healthcare providers favor creams due to their simplicity of application and user-friendliness. Their smooth consistency allows for even coverage over the wound area, enabling non-restrictive application. Due to these factors, creams are prominent in the market. Catering to a wide range of wound care needs and offering a user-friendly option for healthcare professionals and patients involved in wound management.Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed the maximum revenue share in the market in 2022. The region boasts a well-established healthcare infrastructure with sophisticated facilities, advanced technologies, and access to innovative wound care solutions. This infrastructure allows for the adoption of cutting-edge wound care agents and therapies. Furthermore, North America has a high prevalence of chronic diseases such as diabetes, obesity, and cardiovascular conditions. These diseases often lead to chronic wounds, driving the demand for topical wound agents and products.The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Smith & Nephew PLC, Teva Pharmaceutical Industries Ltd., Molnlycke Health Care AB, Viatris, Inc. (Mylan N.V.), AstraZeneca PLC, Coloplast Group, Novartis AG, Pfizer Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), and ConvaTec Group PLC.
Scope of the Study
Market Segments Covered in the Report:
By End-use- Hospitals- Clinics
- Others
- Pressure Ulcers
- Venous Leg Ulcers
- Others
- Acute Wounds- Surgical & Traumatic
- Burns
- Gels
- Sprays
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Smith & Nephew PLC
- Teva Pharmaceutical Industries Ltd.
- Molnlycke Health Care AB
- Viatris, Inc. (Mylan N.V.)
- AstraZeneca PLC
- Coloplast Group
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- ConvaTec Group PLC
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Topical Wound Agents Market by End-use
Chapter 5. Global Topical Wound Agents Market by Application
Chapter 6. Global Topical Wound Agents Market by Product
Chapter 7. Global Topical Wound Agents Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- Smith & Nephew PLC
- Teva Pharmaceutical Industries Ltd.
- Molnlycke Health Care AB
- Viatris, Inc. (Mylan N.V.)
- AstraZeneca PLC
- Coloplast Group
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- ConvaTec Group PLC
Methodology
LOADING...
